Newsroom | 49725 results

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to two newly hired non-executive employees consisting of options to purchase an aggregate of 28,640 common shares of the Company (the “Options”) with...

BRISBANE, Australia e BOSTON--(BUSINESS WIRE)--  AdvanCell annuncia una collaborazione e un accordo esclusivo di licenza con 48Hour Discovery per sviluppare il nuovo farmaco radioterapico a base di peptidi di piombo-212 (212Pb) per il trattamento del carcinoma gastrointestinale con esigenze mediche significative AdvanCell, un’azienda radiofarmaceutica operante nella fase clinica che sviluppa innovative terapie alfa mirate per il trattamento del cancro, oggi ha annunciato la firma di un Accordo...

BRISBANE, Australie et BOSTON--(BUSINESS WIRE)--  AdvanCell annonce avoir passé un accord exclusif de collaboration et de licence exclusive avec 48Hour Discovery pour développer une nouvelle solution radiothérapeutique à base du peptide Lead-212, destinée au traitement d’un cancer gastro-intestinal pour lequel les besoins médicaux sont importants AdvanCell, une société pharmaceutique spécialisée dans le développement clinique de thérapies alpha ciblées innovantes contre le cancer, a annoncé auj...

BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--AdvanCell, una empresa de radiofármacos en fase clínica que desarrolla innovadoras terapias alfa dirigidas contra el cáncer, ha anunciado hoy que ha firmado un acuerdo de colaboración y licencia exclusiva con 48Hour Discovery para desarrollar una novedosa radioterapia con péptidos Lead-212 (212Pb), con un enfoque inicial en el cáncer gastrointestinal, que presenta importantes retos médicos. Esto refleja la estrategia de AdvanCell de crear una línea...

BRISBANE, Australië & BOSTON--(BUSINESS WIRE)--  AdvanCell kondigt samenwerking en exclusieve licentieovereenkomst aan met 48Hour Discovery voor de ontwikkeling van een nieuw, op peptiden gebaseerd, Lead-212 radiotherapeutisch middel voor een gastro-intestinale kanker met een aanzienlijke medische behoefte AdvanCell, een radiofarmaceutisch bedrijf in de klinische fase dat innovatieve gerichte alfatherapieën voor kanker ontwikkelt, heeft vandaag aangekondigd dat het een samenwerkings- en exclusi...

BRISBANE, Australien & BOSTON--(BUSINESS WIRE)--AdvanCell, ein in der klinischen Phase tätiges Radiopharmaunternehmen, das innovative zielgerichtete Alpha-Therapien für Krebs entwickelt, kündigte heute den Abschluss einer Kooperations- und Exklusivlizenzvereinbarung mit 48Hour Discovery zur Entwicklung eines neuartigen peptidbasierten Blei-212-Radiotherapeutikums (212Pb) zu entwickeln. Der Schwerpunkt liegt zunächst auf Magen-Darm-Krebs, für dessen Behandlung ein erheblicher medizinischer Bedar...

YARDLEY, Pa.--(BUSINESS WIRE)--Red Nucleus, a leading provider of strategic services across research and development, medical affairs, market access, commercial, and learning & development, today announced that it has acquired Bridge Medical Consulting, a specialized health economics and outcomes research (HEOR) consultancy. The acquisition represents a key step in Red Nucleus’s strategy, strengthening its ability to help biopharmaceutical companies demonstrate the clinical and economic val...

SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs. Building on early success in Praxis’s innovative Essential3 Program for Essential Tremor, SEQ...

MINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel prophylactic Medical Countermeasures for warfighters, first responders, and others at risk of radiation exposure from nuclear incidents, industrial accidents, or cancer radiation therapy, today announced that RADM Colin G. Chinn, MC, USN (Ret), MD, the Company’s Chief Medical Officer, will be presenting at the Big Idea CONNECTpreneur Baltimore Forum on February 05,...

ORLANDO, Fla.--(BUSINESS WIRE)--Massive Bio today announced the launch of TrialRelay™, a physician-facing enrollment orchestration platform designed to eliminate one of oncology’s most persistent failures: patients getting lost after a clinical trial referral. The announcement will be made during the SCOPE Conference 2026, the leading global forum for clinical operations and innovation. For years, Massive Bio’s physician platform operated under the name Clinical Network. While accurate, the ter...